Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)
Mes dernières consult.
Most popular
  Report  
Real-time Quote. Real-time Tradegate - 04/25 07:11:10 pm
65.11 EUR   -0.57%
06:13pUCB FIRST THREE :  UCB tracking …
PU
04/04UCB : Transparency notification The Capital Group Companies Inc
AQ
04/04UCB : Acquisition of own shares
AQ
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 Analysis summary4-Traders Strategies
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 63.93 EUR in weekly data.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The group usually releases upbeat results with huge surprise rates.
  • The stock is in a well-established, long-term rising trend above the technical support level at 63.93 EUR
Weaknesses
  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • Analysts covering the stock have recently lowered their earnings forecast.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
UCB-1.06%15 652
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398
AMGEN0.44%116 720
ABBOTT LABORATORIES3.10%102 754
SANOFI-8.95%100 817
GLAXOSMITHKLINE10.56%100 086
BAYER-5.80%99 785
NOVO NORDISK A/S-13.71%91 802
ASTRAZENECA-2.57%88 540
ELI LILLY AND COMPANY-5.04%87 635
BRISTOL-MYERS SQUIBB COMPAN..-16.94%83 223
CELGENE CORPORATION-14.25%67 308
More Results
Financials (€)
Sales 2018 4 545 M
EBIT 2018 1 104 M
Net income 2018 757 M
Finance 2018 110 M
Yield 2018 1,90%
P/E ratio 2018 16,30
P/E ratio 2019 14,37
EV / Sales 2018 2,80x
EV / Sales 2019 2,58x
Capitalization 12 814 M
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes
Chart UCB
Duration : Period : Day
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Duration : Period : Week
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders